Clinical trials: in Guinea
COVID-19, Vaccine Adverse Reaction
Evaluation of the Immunogenicity and Safety BBIBP-CorV Vaccine for COVID-19 in Adults in Guinea
Phase II, non-randomized, open-label, comparative, single center national trial in Guinea, aimed to assess the humoral vaccine immune response induced by BBIBP-CorV vaccine in 200 adults aged between 18 and 45 years or 55 or…
- Conditions
- COVID-19, Vaccine Adverse Reaction, Sars-CoV-2 Infection, Healthy Volunteer
- Trial name
- CovicompareG (NCT05409300)
- Testing
- BBIBP-CorV
- Where
- 2 sites in Guinea
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Malaria
Malaria Prevalence Around Maferinyah, Guinea
Background: Many women in Sub-Saharan Africa get malaria while they are pregnant. Plasmodium falciparum is a parasite that can cause malaria. Placental malaria (PM) caused by P.
- Trial name
- NCT04105855
- Where
- Guinea
- Volunteers
- 3,392 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Febrile Illness
Febrile Illness in Guinea
To date, the underlying causes of community-acquired fever, particularly non-malarial fever, are insufficiently documented in Guinea.
- Trial name
- MuSIFe (NCT06122259)
- Where
- Guinea
- Volunteers
- 2,500 people
- Sponsor
- Centre National de Formation et de Recherche en Sante Rurale
Pulmonary Tuberculosis
A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis
In this trial, the investigators are assessing whether giving an increased dose of rifampicin to patients receiving the standard treatment for tuberculosis is safe and, when given for 4 months only, will also result in greater…
- Trial name
- RIFASHORT (NCT02581527)
- Testing
- Rifampicin, Isoniazid, Ethambutol
- Where
- 6 sites in Botswana, Guinea and 4 more
- Volunteers
- 672 people
- Sponsor
- St George's, University of London
HIV Infections
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy
D²EFT is a randomised, open-label study in HIV-1 infected patients failing first-line antiretroviral therapy (ART). The study compares 2 regimens of second-line ART (dolutegravir and darunavir pharmaco-enhanced with ritonavir and…
- Trial name
- D²EFT (NCT03017872)
- Testing
- NRTIs, Dolutegravir, Darunavir
- Where
- 28 sites in Argentina, Brazil and 12 more
- Volunteers
- 831 people
- Sponsor
- Kirby Institute
Tuberculosis, Multidrug-Resistant
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
Recent advances in molecular diagnostics of tuberculosis, especially the GeneXpert Mycobacterium tuberculosis/Rifampicin test have reduced the time to diagnose Rifampicin Resistant Tuberculosis (RR-TB) but only rifampicin…
- Trial name
- DIAMA (NCT03303963)
- Testing
- Deeplex test, MolBio TrueNat for 2nd line, GeneXpert 2nd line, Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value, pre-rRNA synthesis
- Where
- 10 sites in Belgium, Benin and 8 more
- Volunteers
- 3,356 people
- Sponsor
- Dissou AFFOLABI
Cholera, Vibrio Cholerae Infection
Immune Response to a Delayed Second Dose of Oral Cholera Vaccine
Immune response to a delayed second dose of oral cholera vaccine A randomized, controlled, non-inferiority immunogenicity trial in Conakry, The Republic of Guinea
- Trial name
- NCT05453253
- Testing
- Delayed second dose of oral cholera vaccine, Euvichol-Plus, Oral cholera vaccine, Euvichol-Plus, according to manufacturer notice
- Where
- Guinea
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Epicentre
Covid19, Covid19 Drug Treatment
Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection
Coverage Africa is a nested study in the large Anticov platform trial that aims to generate data on new early treatment strategies for mild/moderate COVID-19 patients in resource-limited-settings to reduce the number progressing…
- Conditions
- Covid19, Covid19 Drug Treatment, Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2 Infection
- Trial name
- COVERAGE-A (NCT04920838)
- Testing
- Nitazoxanide and Ciclésonide, Telmisartan 20Mg Oral Tablet, Paracetamol
- Where
- 2 sites in Burkina Faso, Guinea
- Volunteers
- 600 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Ebola
GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Background: Some people have Ebola virus in their body for months after they recover from Ebola virus disease. Some may have health problems from the virus while others are fine.
- Trial name
- NCT02818582
- Testing
- GS-5734
- Where
- 2 sites in Guinea, Liberia
- Volunteers
- 38 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ebola Virus Disease
Prophylaxis Vaccine Antibodies Ebola
Three measures are currently being implemented to control Ebola outbreaks: Monitoring of contacts Isolation and treatment of sick people Vaccination of the population in high-risk areas.
- Trial name
- PROVAE (NCT04822376)
- Testing
- ansuvimab, Ervebo
- Where
- Guinea
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Covid19
Africa COVID-19 Vaccine Hesitancy
Vaccine hesitancy is defined by the WHO's Strategic Advisory Group of Experts on Immunization as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services'.
- Trial name
- ACHES (NCT04912284)
- Where
- 5 sites in Burkina Faso, Guinea and 3 more
- Volunteers
- 4,977 people, healthy volunteers welcome
- Sponsor
- Bernhard Nocht Institute for Tropical Medicine
Covid19
COVID-19 STAndard of Care in Sub-Saharan Africa
This study was conducted in three African countries on four COVID-19 care centers (CCCs). The CCCs were set up in collaboration with a medical NGO with long experience in recording and monitoring data for cohorts and clinical…
- Trial name
- COVISTA (NCT04885543)
- Where
- 3 sites in Burkina Faso, Guinea
- Volunteers
- 2,495 people
- Sponsor
- Alliance for International Medical Action
African Trypanosomiases, West African; Trypanosomiasis
Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection
The study determines the diagnostic performance and cost of rapid diagnostic tests (RDTs) performed on human African trypanosomiasis clinical suspects in peripheral health centres, whether or not followed by serological and/or…
- Conditions
- African Trypanosomiases, West African; Trypanosomiasis, Sleeping Sickness; West African, Trypanosoma Brucei Gambiense; Infection
- Trial name
- DiTECT-WP2 (NCT03356665)
- Testing
- Rapid diagnostic test (RDT), Serological and molecular tests on DBS
- Where
- 3 sites in Côte d’Ivoire, Democratic Republic of the Congo and 1 more
- Volunteers
- 10,700 people
- Sponsor
- Institut de Recherche pour le Developpement
Ebola Virus Disease, Prevention
International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi
The purpose of this study is to evaluate immunogenicity, epidemiological efficacy and safety of medicinal product GamEvac-Combi - Combined Vector-Based Vaccine against Ebola Virus Disease, 0.5 ml+0.5 ml/dose
- Trial name
- NCT03072030
- Testing
- GamEvac-Combi (vaccine)
- Where
- 2 sites in Guinea, Russia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Covid19
Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients
Our previous work on plants has indicated significant antimalarial and antiviral activities. Of these plants, two recipes are proposed for evaluation for COVID-19.
- Trial name
- PHYTCOVID-19 (NCT04501965)
- Testing
- Hydroxychloroquine/Azithromycine, Quinquina-Stevia/Azythromycin, 4Plants/Azythromycin
- Where
- Guinea
- Volunteers
- 231 people
- Sponsor
- Institute for Research and Development of Medicinal and Food Plants of Guinea
Covid19
Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients
The phase II clinical trial, with three arms and at rate of 10 patients per arm, received the approval of the National Committee for Ethics and Health Research.
- Trial name
- CANCOVID-19 (NCT04502342)
- Testing
- Hydroxycloroquine and Azythromycine, Cospherunate/Azythromycine, Cospherunate/Phytomedicine/Azythromycien
- Where
- Guinea
- Volunteers
- 30 people
- Sponsor
- Institute for Research and Development of Medicinal and Food Plants of Guinea
Mother to Child HIV Transmission
HIV Diagnosis and Treatment at Birth for Newborn With High Risk HIV Exposure
Principal objective Assess the operational efficacy of a strategy combining early diagnosis and preventive antiretroviral treatment systematically reinforced from the birth* among infants at high risk of infection with HIV** .
- Trial name
- DIAVINA (NCT03642704)
- Testing
- Reinforced preventive ARV therapy
- Where
- Guinea
- Volunteers
- 56 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hemorrhagic Fever, Ebola
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
This is an emergency, phase 2/3, open-label, non-randomized, clinical trial that will evaluate Convalescent Plasma (CP) added to standardized supportive care (SC) in patients with confirmed Ebola Virus Disease (EVD).
- Trial name
- Ebola-Tx (NCT02342171)
- Testing
- Convalescent Plasma
- Where
- Guinea
- Volunteers
- 606 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola Virus Infection
Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection
Background: Ebola is a viral infection that can spread quickly and causes life-threatening disease. Right now there is an Ebola outbreak in many countries in West Africa. There are no approved treatments for Ebola.
- Trial name
- NCT02363322
- Testing
- B/Current Standard of Care Plus ZMapp, A/Current Standard of Care Alone
- Where
- 11 sites in United States, Guinea and 2 more
- Volunteers
- 72 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Acute Coronary Syndrome, Heart Failure
A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa
FEVRIER study is an observatory of hospitalizations in cardiology units in sub-Saharan Africa.
- Conditions
- Acute Coronary Syndrome, Heart Failure, Syncope, Stroke
- Trial name
- FEVRIER (NCT03231449)
- Testing
- observation of current care
- Where
- 20 sites in Benin, Burkina Faso and 11 more
- Volunteers
- 5,000 people
- Sponsor
- Cardiologie et Développement